Tag Archives: bamlanivimab

Lilly Receives $625M Army Contract Modification for COVID-19 Antibody Therapy

Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army. Army Contracting Command obligated the full amount of the modification using fiscal 2021 Coronavirus Aid, Relief and Economic Security Act funds, …

Read More »